Journal Article Summary
The article discusses the impact of obesity on the effectiveness of short-acting hormonal contraceptives, a topic of increasing importance as obesity rates rise among women of reproductive age in the U.S. The authors highlight that traditional clinical trials often included limited and selective populations, which may not accurately reflect the diverse experiences of women using these contraceptives. Understanding how body mass index (BMI) affects contraceptive efficacy is crucial for both healthcare providers and patients in making informed choices about birth control methods.
The authors reviewed existing studies and data on the relationship between obesity and contraceptive failure rates. They found that while earlier trials did not specifically exclude obese women, the average weight of participants was often lower, potentially skewing results. Recent analyses indicated that obese women (with a BMI of 30 or higher) may experience higher rates of unintended pregnancies when using hormonal contraceptives compared to their non-obese counterparts, suggesting that obesity could be a significant factor in contraceptive effectiveness.
However, the article also notes several limitations, including the reliance on retrospective data and the need for more prospective studies that include diverse populations. Patients should be aware that while obesity may influence contraceptive effectiveness, hormonal contraceptives are still generally more effective than barrier methods. It is recommended that individuals discuss their weight and any concerns about contraceptive options with their healthcare providers to ensure they choose the most suitable method for their needs.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Edelman Alison, Trussell James, Aiken Abigail R.A., Portman David J., Chiodo Joseph A., Garner Elizabeth I. O.. The emerging role of obesity in short-acting hormonal contraceptive effectiveness. Contraception 2017. DOI: 10.1016/j.contraception.2017.12.012. PMID: 29269251. PMCID: PMC6049839.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) --- Perrigo --- Over The Counter
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) — Perrigo — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
